Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NeoImmuneTech, Inc. (NIT) acquired the exclusive worldwide rights to research, develop, and commercialize drug candidates, in exchange for development and sales milestones, as well as royalties.
Lead Product(s): NT-I7
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: NeoImmuneTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 23, 2020